Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Next Nutrition Challenging SportPharma Actisyn Muscle Building Claims

This article was originally published in The Tan Sheet

Executive Summary

Next Nutrition is challenging SportPharma claims that the latter's Actisyn protein synthesizer "helps build muscle 640% better than whey protein," in a suit filed in San Diego federal court. Carlsbad, Calif.-based Next Nutrition, which markets competing protein supplements, including ion-exchanged whey, alleges the SportPharma claims of superiority are false and misleading.

You may also be interested in...



Weider NuStart Breast Health Print Ad Discontinued Following NAD Inquiry

Weider Nutrition International "immediately and permanently" discontinued advertising for its NuStart Breast Health Formula in response to an investigation by the Council of Better Business Bureaus' National Advertising Division, according to a NAD case brief.

Weider NuStart Breast Health Print Ad Discontinued Following NAD Inquiry

Weider Nutrition International "immediately and permanently" discontinued advertising for its NuStart Breast Health Formula in response to an investigation by the Council of Better Business Bureaus' National Advertising Division, according to a NAD case brief.

Weider NuStart Breast Health Print Ad Discontinued Following NAD Inquiry

Weider Nutrition International "immediately and permanently" discontinued advertising for its NuStart Breast Health Formula in response to an investigation by the Council of Better Business Bureaus' National Advertising Division, according to a NAD case brief.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS089817

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel